Exploring the Olfactory Mucosa, Blood and Urine for the Identification of Early Biomarkers of Parkinson's Disease, Atypical Parkinsonisms and Neurocognitive Disorders Due to Lewy Body Disease

Status: Recruiting
Location: See all (3) locations...
Study Type: Observational
SUMMARY

Clinical diagnosis of Parkinson's disease (PD), multiple system atrophy (MSA) and dementia with Lewy bodies (DLB) is challenging, especially in the early stages. Each disease is associated with distinct conformers of misfolded alpha-synuclein (maS) which form typical protein aggregates in the brain and represent key disease biomarkers. Thus, detection and characterization of intracerebral maS aggregates allow a definite diagnosis. The recent development of ultrasensitive assays enabled the detection of maS and other potential new biomarkers in peripheral tissues, although with several limitations. Here, the investigators propose to combine the expertise of leading and young researchers in the field of neurology, structural and molecular biology, biophysics and machine learning to perform ultrasensitive and multi-omics analyses of olfactory mucosa (OM), blood and urine of PD, MSA and DLB patients for detecting and characterizing key peripheral biomarkers allowing accurate disease recognition.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: t
View:

• PD (Postuma et al., 2015), MSA (Palma et al., 2018), DLB (McKeith et al., 2017), OND including acquired and hereditary ataxic syndrome with known etiology, progressive supranuclear palsy, corticobasal degeneration, and motor neuron disease.

Locations
Other Locations
Italy
IRCCS Centro San Giovanni di Dio
RECRUITING
Brescia
Fondazione IRCCS Istituto Neurologico Carlo Besta
RECRUITING
Milano
Consorzio Interuniversitario Risonanze Magnetiche Metallo Proteine (CIRMMP)
RECRUITING
Sesto Fiorentino
Time Frame
Start Date: 2023-10-03
Estimated Completion Date: 2026-04
Participants
Target number of participants: 180
Sponsors
Leads: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

This content was sourced from clinicaltrials.gov